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integrins. Particularly for tumor cells its remains critical that therapy 
resistance emerges from mutually and cooperatively interactions 
between integrins and transmembrane growth factor receptors. How 
exactly such interactions are executed and what consequences result 
from them for tumor cell behavior and bypass signaling for therapy 
resistance will be the great challenge to understand in the next years. 
Additional impact on these processes arises from extracellular matrix 
stiffness in tumors, which is commonly observed relative to normal 
tissues. Despite the fact that ECM stiffness essentially contributes to 
tumor progression, it remains unclear what its role is for tumor cell 
resistance to standard radio(chemo)therapy. What our current view on 
the above mentioned aspects of tumor biology and therapy resistance 
is will be presented. 
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Hypoxia is a common feature of tumors and an important contributor 
to malignancy and treatment resistance. We and others have shown 
that a lysosomal degradation pathway, autophagy, which enables cells 
to recycle and redirect nutrients to adapt to metabolic stresses, is 
required for the survival of hypoxic cells. Consequently, autophagy 
inhibition sensitized tumors to irradiation as determined by tumor 
growth delay experiments.   
Our research focuses on unraveling the molecular mechanisms that 
are required for the activation of autophagy during hypoxia and to 
exploit these for therapeutic purposes. During this presentation, I will 
describe some of our recent findings and how we think that we can 
use autophagy targeting to improve tumor treatment. For example, 
we identified a radioresistant subset of glioblastoma that, when 
metabolically challenged, is highly dependent on autophagy for 
survival.  Its dependency on autophagy provides a novel opportunity to 
delay recurrence of the tumors after treatment.  
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Tumor hypoxia is associated with aggressive disease and poor clinical 
outcome in many types of cancer. This is due in large part to the 
ability of hypoxia to influence important signalling pathways that 
augment metabolism, angiogenesis, genetic instability, and 
metastasis. Recent data suggests that hypoxia may also promote 
stemness in normal stem cell microenvironments, and in the oxygen 
deprived microenvironments of some solid tumors. We have 
discovered a novel potential mechanism that may underlie these 
observations. We found that hypoxia causes a rapid loss of the enzyme 
DICER, an essential component in the miRNA biogenesis pathway. This 
occurs through an epigenetic mechanism that results in transcriptional 
silencing of the DICER1 gene. Loss of DICER during hypoxia or 
following genetic knockdown results in a defect in the creation of 
mature and functional miRNA, and a corresponding increase in miRNA 
precursor forms. However, loss of DICER has a differential effect on 
individual miRNAs and resulted in a particular loss of members of the 
miR200 family. Loss of mIR200 during hypoxia or following DICER1 
knockdown results in derepression of its target ZEB1 and induces an 
epithelial-mesenchymal transition (EMT) characterized by an altered 
cell morphology, loss of E-cadherin, and acquistion of N-cadherin and 
vimentin. In human mammary epithelial cells transformed with 
dominant oncogenes, exposure to hypoxia or knockdown of DICER1 
induces EMT and acquisition of stem cell properties including 
increased sphere formation, and expression of the cell surface 
markers CD24low,CD44high which have been shown to enrich in tumor 
initiating cells.  Importantly, both EMT and acquisition of stem cell 
properties are prevented during hypoxia by overexpression of 
mIR200b. DICER1 and hypoxia were also found to be negatively 
correlated in a large clinical series of breast cancer gene expression 
studies and both low DICER expression and high hypoxia were 
associated with poor outcome. Collectively, these data indicate that 
hypoxic suppression of DICER leads to increased stemness through 
repression of the mIR200 family and suggest this effect may 
contribute to the known association of hypoxia with metastasis and 
poor outcome in patients.  
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There is no doubt that the story of Medical Physics has been a story of 
incredible success. Academic and professional contributions that 
Medical Physics has made in the areas of radiation therapy and 
imaging are too many to list. The academic advances have been 
successfully translated to the clinics, leading to wide recognition of 
Medical Physics as an essential health profession. This success has lead 
to maturation of the field, reflected in strong consolidation of the 
professional part of Medical Physics. Particularly in the US, this 
consolidation has been accelerated with the recently implemented 
strict CAMPEP (Commission on Accreditation of Medical Physics 
Educational Programs) requirements that have tightened education 
and training requirements for Medical Physics professionals, leaving 
little room for academic freedom and expansion of the field. This 
consolidation exposed challenges in front of the academic part of 
Medical Physics. 
Concerned about the long-term future of Medical Physics as an 
academic and professional discipline, the American Association of 
Physicists in Medicine (AAPM) has established a Working Group on the 
Future of Medical Physics Research and Academic Training (WG 
FUTURE) with a charge “to initiate, coordinate and lead activities to 
secure sustainable growth and improvement in the long-term future 
environment for high quality research and academic training of 
physicists in medicine”. WG FUTURE has already had a significant 
impact through development of the AAPM Research Strategic Plan, 
organization of a series of “Expanding Horizons” workshops and 
initiation of many other activities.  
In this talk, the activities of WG FUTURE will be outlined, particularly 
activities of high interest to the ESTRO members. In additional, 
potential synergistic activities will be proposed to further strengthen 
global collaboration of medical physicists and secure long-term future 
of the field. 
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In the question how the physicist retains responsibility for the patient, 
is related to the legal as well as ethical considerations. In this paper 
we will provide an overview of the legal implications in different 
countries of the ESTRO membership as well as the US. 
On an ethical level there is a need to decide to what level the 
physicist carries responsibility. It is clear however that the physicist is 
definitely responsible in providing the tools to the physician and to 
make sure these tools provide the advertised accuracy and quality 
control for these tools needs to be available.  
On the other hand when the patient is being treated it is still the 
physicians' responsibility to decide which treatment (if any) will be 
most beneficial to the patient.  
The question then remains: "which is the physicist's responsibility?" 
By using specific examples from errors and use cases we will 
investigate the different possibilities. Finally, a town hall round of 
questions is started to start discussions.  
   
SP-0648   
Future developments of medical physics inside and outside 
radiotherapy  
D.R. Olsen 
Faculty of Mathematics and Natural Sciences, University of Bergen, 
Norway 
 
Abstract not received 
 
